Search

Displaying results 7311 - 7320 of 8412 in total
  1. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  2. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  3. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.

  4. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech.

  5. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence

  6. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  7. Drug

    D-Glutamine

    go.drugbank.com/drugs/DB02174
    Experimental

    It is the principal carrier of nitrogen in the body and is an important energy source for many cells.

    Synonyms: D-Glutamin, D-Glutamine
  8. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    It is used as an analytical reagent and general reducing agent. [PubChem]

  9. Drug

    Teprenone

    go.drugbank.com/drugs/DB15955
    Investigational

  10. Drug

    XC221

    go.drugbank.com/drugs/DB16503
    Investigational

    XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.